| Case Number | 12036 |
| Request Date | 29/07/2026 |
| Completion Date | 24/08/2026 |
Details of the Request
I am conducting analysis on the use of biologic medicines in secondary care and kindly request your help.
I would be grateful if you could respond with the number of patients treated with specific medicines between the start of April 2026 and the end of June 2026, or the latest three-month period for which data is available. Please include data for all hospitals in your organization.
- How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?
- How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of April 2026 and end of June 2026?
- How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of April 2026 and end of June 2026?
Details of the Response
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?
| Name of Medicine | Number of Patients Treated |
| 1.1) Benralizumab (Fasenra) | 0 |
| 1.2) Depemokimab (Exdensur) | 0 |
| 1.3) Dupilumab (Dupixent) | 72 |
| 1.4) Mepolizumab (Nucala) | 0 |
| 1.5) Omalizumab (Xolair) | 24 |
| 1.6) Reslizumab (Cinqaero) | 0 |
| 1.7) Tezepelumab (Tezspire) | 0 |
Q2. How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of April 2026 and end of June 2026?
| Name of Medicine | Severe Asthma (please include all types or references to asthma) | Chronic Obstructive Pulmonary Disease (COPD) | Chronic Rhinosinusitis with Nasal Polyps (CRwNP) |
| 2.1) Benralizumab (Fasenra) | 0 | ||
| 2.2) Depemokimab (Exdensur) | 0 | ||
| 2.3) Dupilumab (Dupixent) | 0 | 0 | 0 |
| 2.4) Mepolizumab (Nucala) | 0 | 0 | 0 |
| 2.5) Omalizumab (Xolair) | 22 | 0 | |
| 2.6) Reslizumab (Cinqaero) 0 | |||
| 2.7) Tezepelumab (Tezspire) | 0 | 0 |
Q3. How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of April 2026 and end of June 2026?
| Name of Medicine | Number of Patients with Atopic Dermatitis | Number of Patients with Chronic Spontaneous Urticaria (CSU) |
| 3.1) Dupilumab (Dupixent) | 4 | 0 |



